Sanofi's third quarter figures are on track but shares fall on diabetes price competition warning

28 October 2014

French drug major Sanofi’s (Euronext: SAN) third-quarter earnings are in focus, but the company’s shares have plummeted more than 7% after it forecast that its key diabetes business would slow.

Sales were up 5.1% to 8.78 billion euros ($11.1 billion), with earnings up 9.4% to 1.94 billion euros. Earnings per share were at 1.47 euros, an increase of 10.3%.

Sanofi's warning on diabetes competition

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical